PDCD1 and neoplasm: Passive immunotherapy is the most frequent form of immunotherapy, involving agents that enhance existing anti-tumour responses, such as antibodies against immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein (1 PD-1), and programmed death-ligand 1 (PD-L1).